球囊扩张式心脏瓣膜外科植入治疗二尖瓣环钙化
该研究描述了对严重二尖瓣环钙化(MAC)患者经左心房直视植入球囊扩张式瓣膜(BEV)的经验,共51例患者,技术成功率为94.1%,30天和1年死亡率分别为13.7%和33.3%。结论认为此法为常规外科高危且经导管途径有左室流出道梗阻风险的患者提供了治疗选择。
要点
- 严重MAC患者外科植入BEV技术成功率94.1%。
- 30天死亡率为13.7%,1年死亡率为33.3%。
- 适用于常规外科高危且经导管有左室流出道梗阻风险者。
核心结论
- 对严重MAC患者,外科植入BEV提供了常规外科高危且经导管有左室流出道梗阻风险时的治疗选择。
研究设计与样本
- 手术经正中开胸或微创入路,直视下经左心房植入BEV,切除前叶中部,必要时行室间隔心肌切除。
主要发现
- 平均年龄73.9±8.8岁,女性占60.8%(31/51),平均STS预测死亡风险6.8%±4.8%。
- 技术成功率为94.1%(48/51)。
- 30天死亡率为13.7%(7/51),1年死亡率为33.3%(15/45)。
- 30天卒中率为3.9%(2/51),1年卒中率为4.4%(2/45)。
关键数值与推荐
- 技术成功定义依据二尖瓣学术研究联盟(MVARC)标准。
- 主要结局为技术成功,次要结局为30天和1年死亡率。
临床怎么用
- 对于严重MAC且常规外科高危、经导管途径有左室流出道梗阻风险的患者,可考虑外科直视下植入BEV。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The treatment of mitral valve disease in the presence of mitral annular calcification (MAC) is associated with an increased risk of cardiovascular and all-cause mortality. Various surgical and transcatheter techniques for the treatment of mitral disease with severe MAC have been described. However, these procedures are associated with high risk of operative morbidity and mortality. We describe our experience with open surgical implantation of a balloon-expandable valve (BEV) in patients with severe MAC as an alternative approach. METHODS: BEV implantation was performed with direct vision through the left atrium via a median sternotomy or minimally invasive approach. The midportion of the anterior leaflet is excised, and a ventricular septal myectomy performed if there is high risk for left ventricular outflow tract obstruction. The primary outcome was technical success according to the Mitral Valve Academic Research Consortium criteria; secondary outcomes were 30-day and 1-year mortality. RESULTS: From October 2015 through October 2020, 51 patients at 2 institutions underwent BEV-in-MAC (mean age, 73.9 ± 8.8 years; 60.8% [31/51] were female; mean Society of Thoracic Surgeons predicted risk of mortality: 6.8% ± 4.8%). Technical success was 94.1% (48/51). Thirty-day and 1-year mortality were 13.7% (7/51) and 33.3% (15/45), and for stroke 3.9% (2/51) and 4.4% (2/45), respectively. CONCLUSIONS: Surgical implantation of a BEV in the mitral position offers a treatment option for patients with mitral valve disease complicated by severe MAC who are at increased risk for conventional surgical approaches and at risk for left ventricular outflow tract obstruction with transcatheter approaches.
引用
- Smith RL, Hamandi M, Ailawadi G, et al. Surgical implantation of balloon-expandable heart valves for the treatment of mitral annular calcification. J Thorac Cardiovasc Surg. 2021. PMID: 34635317. doi:10.1016/j.jtcvs.2021.08.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。